Search Result

Results for "

LSD

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (22) Bcl-2 Family (1) Caspase (2) DNA/RNA Synthesis (1) Dopamine Receptor (3) E1/E2/E3 Enzyme (1) Estrogen Receptor/ERR (1) Fluorescent Dye (1) Glucosidase (3) HDAC (8) Histone Demethylase (97) Histone Methyltransferase (3) HSP (1) HSV (2) IAP (1) MAP3K (2) MDM-2/p53 (2) Microtubule/Tubulin (1) Monoamine Oxidase (17) PD-1/PD-L1 (3) Phosphatase (2) ROS Kinase (2) TGF-beta/Smad (1) TNF Receptor (1)
By Research Areas:	Cancer (88) Cardiovascular Disease (8) Endocrinology (2) Infection (6) Inflammation/Immunology (2) Metabolic Disease (5) Neurological Disease (14)
Click Chemistry:	Alkynes (2)

113

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-155115

LSD1-IN-27	Histone Demethylase PD-1/PD-L1	Cancer
LSD1-IN-27 (Compound 5ac) is a *LSD1* inhibitor (IC₅₀: 13 nM). LSD1-IN-27 inhibits the stemness and migration of gastric cancer cells. LSD1-IN-27 also reduces the expression of PD-L1 in BGC-823 and MFC cells. LSD1-IN-27 can enhance T cell immune response in gastric cancer .

HY-P4091

*LSD*	Fluorescent Dye	Cancer
LSD is a conjugate with phthalocyanine dye for photoimmunoresearch research .

HY-161849

LSD1-IN-31	Histone Demethylase	Metabolic Disease
LSD1-IN-31 (compound 11e) can directly bind to LSD1/CoREST complex to reduce LSD1 demethylation enzymatic activity. LSD1-IN-31 inhibits LSD1 demethylation activity and influences its downstream IκB/NF-κB signaling pathway. LSD1-IN-31 inhibits osteoclastic bone loss in vitro and in vivo. LSD1-IN-31 can be used for osteoporosis research .

HY-168504

LSD1-IN-36	Histone Demethylase Apoptosis	Cancer
LSD1-IN-36 is a potent *LSD1* inhibitor with an IC₅₀ value of 0.8 nM. LSD1-IN-36 induces apoptosis and arrests the cell cycle. LSD1-IN-36 shows antitumor activity .

HY-152032

LSD1-IN-23	Histone Demethylase	Cancer
LSD1-IN-23 is a competitive/non-competitive mixed inhibitor of lysine specific demethylase 1 (LSD1). LSD1-IN-23 has LSD1 inhibitory activity with an IC₅₀ value of 0.58 μM. LSD1-IN-23 can be used for the research of neuroblastoma (NB) .

HY-144756

LSD1-IN-15	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-15 (compound 1b) is a potent *LSD1* inhibitor. LSD1-IN-15 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.149, 0.028, and 0.327 μM, respectively. LSD1-IN-15 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 9.9 μM .

HY-144757

LSD1-IN-16	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-16 (compound 4b) is a potent *LSD1* inhibitor. LSD1-IN-16 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.015, 0.024, and 0.366 μM, respectively. LSD1-IN-16 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 15.2 μM .

HY-144758

LSD1-IN-17	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-17 (compound 5b) is a potent *LSD1* inhibitor. LSD1-IN-17 can inhibit *LSD1-CoREST, MAO-A* and MAO-B, with IC₅₀ values of 0.005, 0.028, and 0.820 μM, respectively. LSD1-IN-17 displays cell growth arrest in prostate cancer LNCaP cells, with an IC₅₀ of 17.2 μM .

HY-149978

LSD1-IN-26	Histone Demethylase Monoamine Oxidase Apoptosis Bcl-2 Family IAP Caspase	Cancer
LSD1-IN-26 (compound 12u) is a potent *LSD1* inhibitor, with an IC₅₀ of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC₅₀=1234.57 nM) and MAO-B (IC₅₀=3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research .

HY-144675

LSD1-IN-13	Histone Demethylase	Cancer
LSD1-IN-13 (compound 7e) is an orally active and potent *LSD1* inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-144675A

LSD1-IN-13 hydrochloride	Histone Demethylase	Cancer
LSD1-IN-13 hydrochloride (compound 7e) is an orally active and potent *LSD1* inhibitor, with an IC₅₀ of 24.43 nM. LSD1-IN-13 hydrochloride can activate CD86 expression, with an EC₅₀ of 470 nM. LSD1-IN-13 hydrochloride induces differentiation of AML (acute myeloid leukemia) cell lines .

HY-161869

LSD1-IN-32	Histone Methyltransferase	Metabolic Disease
LSD1-IN-32 (compound 11e) is a potent *LSD1* inhibitor with an IC₅₀ value of 0.99 µM. LSD1-IN-32 inhibits RANKL-induced osteoclastogenesis, bone resorption and F-actin belt formation. LSD1-IN-32 has the potential for the research of osteoporosis .

HY-100859

LSD1-IN-5	Histone Demethylase	Cancer
LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-100860

LSD1-IN-6	Histone Demethylase	Cancer
LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-151191

LSD1-IN-22	Histone Demethylase	Cancer
LSD1-IN-22 is a potent Lysine-specific demethylase 1 (LSD1) inhibitor with a K_i value of 98 nM. LSD1-IN-22 has anti-proliferative activity against certain cancer cells .

HY-149968

LSD1-IN-25	Histone Demethylase Apoptosis	Cancer
LSD1-IN-25 (Compound 9j) is a potent, selective and orally active *LSD₁* inhibitor with an IC₅₀ of 46 nM (K_i = 30.3 nM). LSD1-IN-25 induces cancer cell apoptosis .

HY-147697

LSD1-IN-21	Histone Demethylase TNF Receptor	Inflammation/Immunology Cancer
LSD1-IN-21 (compound 5a) is a potent and BBB-penetrated *LSD1* (Lysine specific demethylase-1) inhibitor, with an IC₅₀ of 0.956 µM. LSD1-IN-21 significantly reduces the pro-inflammatory cytokine TNF-α. LSD1-IN-21 shows good anticancer and anti-inflammatory activity .

HY-162729

LSD1-IN-34	Histone Demethylase Monoamine Oxidase TGF-beta/Smad	Cardiovascular Disease
LSD1-IN-34 (Compound 7d) is the orally active inhibitor for Lysine-specific demethylase (LSD) and monoamine oxidase (MAO), with IC₅₀ of 4.51 and 18.46 nM, for *LSD1* and MAO A. LSD1-IN-34 inhibits the Ang II-induced neonatal rat myocardial fibroblasts (NRCFs) activation, without significant toxicity (20 μM). LSD1-IN-34 inhibits TGFβ/Smad signaling pathway, and ameliorates heart failure in mice. LSD1-IN-34 exhibits good pharmacokinetic characteristics in rats .

HY-151192

LSD1/2-IN-3	Histone Demethylase	Cancer
LSD1/2-IN-3 is a selective inhibitor of lysine-specific demethylase 1 (LSD1), with a K_i value of 11 nM instead of 7 μM for *LSD2. There is aberrant expression of LSD1* in cancer stem cells, LSD1/2-IN-1 inhibits *LSD1* cell proliferation .

HY-151194

LSD1/2-IN-4	Histone Demethylase	Cancer
LSD1/2-IN-4, a PCPA derivative, is an inhibitor of lysine-specific demethylase 1 (LSD1) and lysine-specific demethylase 2 (LSD2). LSD1/2-IN-4 inhibits LSD1 and LSD2 with K_i values of 0.11 μM and 130 μM, respectively. LSD1/2-IN-4 can be used for the research of several cancers including T-cell acute lymphoblastic leukemia (TALL) .

HY-144673

LSD1-IN-12	Histone Demethylase Monoamine Oxidase	Cancer
LSD1-IN-12 (compound 2) is a potent *LSD1* inhibitor, with K_i values of 1.1 μM (LSD1), 61 μM (LSD2), 2.3 μM (MAO-A), and 3.5 μM (MAO-B), respectively .

HY-168086

LSD1-IN-35	PD-1/PD-L1 Histone Demethylase	Infection Inflammation/Immunology
LSD1-IN-35 (Compound Z-1) is a selective *LSD1* Inhibitor (IC₅₀: 108 nM). LSD1-IN-35 inhibits the demethylation on H3K4me1/2. LSD1-IN-35 is an immunomodulator. LSD1-IN-35 promotes response of gastric cancer cells to T-cell killing effect by decreasing PD-L1 expression and further attenuates the PD-1/PD-L1 interaction .

HY-145861

LSD1-IN-14	Histone Demethylase Apoptosis	Cancer
LSD1-IN-14 is a potent and selective *LSD1* inhibitor (IC₅₀=0.89 μM). LSD1-IN-14 can significantly inhibit the proliferation of A549 and THP-1 cells and induce the apoptosis of tumor cells .

HY-160183

LSD1-IN-29	Histone Demethylase	Cancer
LSD1-IN-29 (compound 6) is a Lysine specific demethylase 1 (LSD1) inhibitor with the IC₅₀ of 19 nM .

HY-149213

LSD1-IN-24	Histone Demethylase PD-1/PD-L1	Cancer
LSD1-IN-24(compound 3S) is a selective *LSD1* inhibitor with IC₅₀ = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research .

HY-160191

LSD1-IN-30	Histone Demethylase	Cancer
LSD1-IN-30 (compound 3) is a potent inhibitor of lysine-specific demethylase 1 (LSD1), with the IC₅₀ value of 0.291 μM .

HY-146285

LSD1-IN-20	Histone Demethylase Histone Methyltransferase	Cancer
LSD1-IN-20 (compound 1) is a potent dual non-covalent *LSD1/G9a* inhibitor, with K_i values of 0.44 and 0.68 μM, respectively. LSD1-IN-20 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.51 and 1.60 μM, respectively .

HY-146440

LSD1/ER-IN-1	Histone Demethylase Estrogen Receptor/ERR Apoptosis	Cancer
LSD1/ER-IN-1 (compound 11g) is a potent ER and *LSD1* inhibitor, with an IC₅₀ of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC₅₀ of 8.79 μM .

HY-149595

LSD1-UM-109	Histone Demethylase	Cancer
LSD1-UM-109 is a ighly potent and reversible *LSD1* inhibitor with an IC₅₀ of 3.1 nM. LSD1-UM-109 inhibits cell growth with IC₅₀ values of 0.6 nM in the MV4;11 acute leukemia cell line and 1.1 nM in the H1417 small-cell lung cancer cell line .

HY-146283

LSD1-IN-18	Histone Demethylase	Cancer
LSD1-IN-18 (compound 7) is a potent, non-covalent and selective *LSD1* inhibitor, with K_i of 0.156 μM and K_D of 0.075 μM, respectively. LSD1-IN-18 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.16 and 0.21 μM, respectively .

HY-146284

LSD1-IN-19	Histone Demethylase	Cancer
LSD1-IN-19 (compound 29) is a potent, non-covalent and selective *LSD1* inhibitor, with K_i of 0.108 μM and K_D of 0.068 μM, respectively. LSD1-IN-19 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.17 and 0.40 μM, respectively .

HY-162955

LSD1/HDAC-IN-1	HDAC Histone Demethylase	Cancer
LSD1/HDAC-IN-1 (compound 2) is a potent inhibitor of HDAC and *LSD1, with IC₅₀s of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8* and *LSD1, respectively. LSD*1/HDAC-IN-1 plays an important role in cancer research .

HY-131970

LSD1/HDAC6-IN-1	Histone Demethylase HDAC	Cancer
LSD1/HDAC6-IN-1 is an orally active dual inhibitor of *lysine specific demethylase 1(LSD1)/Histone deacetylase 6 (HDAC6), with anti-tumor activity. LSD*1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM) .

HY-163859

LSD1-IN-33	Histone Demethylase	Cardiovascular Disease
LSD1-IN-33 (7d), an orally active *LSD1* inhibitor with an IC₅₀ of 4.51 nM, alleviates Ang II-induced NRCFs activation in vitro and reducing pathological myocardial remodeling in TAC-induced cardiac remodeling and heart failure in vivo .

HY-164099

LSD1/HDAC6-IN-2	HDAC Monoamine Oxidase Histone Demethylase	Cancer
LSD1/HDAC6-IN-2 (JBI-802) is an orally active *LSD1/HDAC6/MAO-A* inhibitor, with IC₅₀ values of 5 nM, 11 nM, and 5 nM, respectively. LSD1/HDAC6-IN-2 can inhibit the growth of multiple myeloma cells MM.1S, MM.1R, and RPMI-8226. LSD1/HDAC6-IN-2 can be used for research on diseases such as acute myeloid leukemia and lymphoma .

HY-129388A

Pulrodemstat CC-90011; LSD1-IN-7	Histone Demethylase	Cancer
Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-129388B

Pulrodemstat benzenesulfonate 2 Publications Verification CC-90011 benzenesulfonate; LSD1-IN-7 benzenesulfonate	Histone Demethylase	Cancer
CC-90011 benzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. CC-90011 benzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 benzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-129388

Pulrodemstat Methylbenzenesulfonate CC-90011 Methylbenzenesulfonate; LSD1-IN-7 Methylbenzenesulfonate	Histone Demethylase	Cancer
CC-90011 Methylbenzenesulfonate is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC₅₀ of 0.25 nM. CC-90011 Methylbenzenesulfonate is less enzymatic inhibition against LSD2, MOA-A, and MAO-B. CC-90011 Methylbenzenesulfonate induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity .

HY-100546

*GSK-LSD1*	Histone Demethylase	Infection Metabolic Disease Cancer
GSK-LSD1 is a *LSD1* inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis .

HY-100546A

*GSK-LSD1 dihydrochloride* 5+ Cited Publications	Histone Demethylase Monoamine Oxidase	Cancer
GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC₅₀ of 16 nM.

HY-169098

*HSP90/LSD1-IN-1*	HSP Histone Demethylase	Cancer
HSP90/LSD1-IN-1 (compound 6) is a *HSP90/LSD1* dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI₅₀ values of 0.24 and 0.30 μM, respectively .

HY-12645

NCL1	Histone Demethylase	Cancer
NCL1 is a phenylcyclopropylamine (PCPA)-based Lysine-specific demethylase 1 (LSD1) inhibitor. NCL1 selectively inhibits LSD1 in preference to LSD2, with IC₅₀ values of 2.5 and 26 μM for LSD1 and LSD2, respectively .

HY-112304

NCD38 TFA	Histone Demethylase	Others
NCD38 TFA is a *LSD1*-selective inhibitor .

HY-161848

TCP-MP-CA	Histone Demethylase	Cancer
TCP-MP-CA (compound 11a) is an inhibitor of LSD1 demethylation enzymatic via binding to LSD1/CoREST complex. TCP-MP-CA exhibits an inhibitory effect on osteoclastogenesis, with an IC₅₀ value of 0.14 µM .

HY-112623

Vafidemstat 1 Publications Verification ORY-2001	Histone Demethylase Monoamine Oxidase	Neurological Disease
Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor .

HY-111048

Corin 3 Publications Verification	Histone Demethylase HDAC	Cancer
Corin is a dual inhibitor of histone lysine specific demethylase *(LSD1)* and histone deacetylase (HDAC), with a K_i(inact) of 110 nM for LSD1 and an IC₅₀ of 147 nM for HDAC1.

HY-168527

Acaricide	Histone Demethylase	Cancer
Acaricide (Compound 7l) is a potent *LSD1* inhibitor. LSD1 exhibits excellent acaricidal activity against egg of T. cinnabarinus with a LC₅₀ of 0.0035 mg/L .

HY-18632A

GSK2879552 dihydrochloride Maximum Cited Publications 15 Publications Verification	Histone Demethylase	Cancer
GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity .

HY-17447A

Tranylcypromine hydrochloride 4 Publications Verification SKF 385 hydrochloride	Monoamine Oxidase	Neurological Disease
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 *(LSD1/BHC110)* and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC₅₀s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression .

HY-112304A

(1R,2S)-NCD38 TFA	Histone Demethylase	Others
(1R,2S)-NCD38 TFA is an enantiomer of NCD38 TFA. NCD38 TFA is a *LSD1*-selective inhibitor .

Cat. No.	Product Name	Target	Research Area

HY-P4091

*LSD*	Fluorescent Dye	Cancer
LSD is a conjugate with phthalocyanine dye for photoimmunoresearch research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2037A

Higenamine hydrochloride 2 Publications Verification Norcoclaurine hydrochloride	Structural Classification Classification of Application Fields Source classification Plants Lindera aggregata (Sims) Kosterm. Alkaloids Phenols Polyphenols Lauraceae Isoquinoline Alkaloids Disease Research Fields Endocrinology Cancer	MAP3K MDM-2/p53 ROS Kinase Apoptosis
Higenamine hydrochloride is a selective *LSD1* inhibitor (IC₅₀=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

HY-N2037AR

Higenamine hydrochloride (Standard)	Alkaloids Structural Classification Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm.	MAP3K MDM-2/p53 ROS Kinase Apoptosis
Higenamine (hydrochloride) (Standard) is the analytical standard of Higenamine (hydrochloride). This product is intended for research and analytical applications. Higenamine hydrochloride is a selective LSD1 inhibitor (IC50=1.47 μM) that can be isolated from aconite. Higenamine hydrochloride has anti-inflammatory and antibacterial activity. Higenamine (Norcoclaurine) can attenuate IL-1β-induced Apoptosis through ROS-mediated PI3K/Akt signaling pathway. Higenamine hydrochloride protects brain cells from oxygen deprivation. Higenamine can promote bone formation in osteoporosis through the SMAD2/3 pathway. Higenamine hydrochloride can be used to study cancer, inflammation, cardiorenal syndrome and other diseases .

Species:	Human (3) Mouse (1)
Tag:	His (2) GST (3)
Source:	Sf9 insect cells (2) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P75551

	LSD1 Protein, Human (sf9, His-GST) Lysine-specific histone demethylase 1A; KDM1A; AOF2; KDM1; KIAA0601; LSD1	Human	Sf9 insect cells
	The LSD1 protein is a histone demethylase that modifies histone H3 by demethylating “Lys-4” (H3K4me) and “Lys-9” (H3K9me).It acts as a coactivator or corepressor, oxidizing substrates via FAD to generate imines that are subsequently hydrolyzed.LSD1 Protein, Human (sf9, His-GST) is the recombinant human-derived LSD1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P71543

	DNASE1L3 Protein, Human (GST) Deoxyribonuclease gamma; Deoxyribonuclease I like 3; Deoxyribonuclease I like III; Deoxyribonuclease I-like 3; DHP 2; DHP2; DNAS1L3; DNase gamma; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I like 3; DNase I-like 3; DNASE1L3; DNSL3_HUMAN; Liver and spleen DNase; LS DNase; LS-DNase; LSD; SLEB 16; SLEB16	Human	E. coli
	DNASE1L3 proteolytically cleaves single- and double-stranded DNA and generates fragments with 3'-OH termini. It can cleave chromatin, nucleosomes, and liposome-coated DNA. DNASE1L3 Protein, Human (GST) is the recombinant human-derived DNASE1L3 protein, expressed by E. coli , with N-GST labeled tag. The total length of DNASE1L3 Protein, Human (GST) is 285 a.a., with molecular weight of ~60.4 kDa.

HY-P703046

	KDM1B Protein, Mouse (sf9, GST) Aof1; LSD2	Mouse	Sf9 insect cells
	KDM1B Protein, Mouse (sf9, GST) is the recombinant mouse-derived KDM1B, expressed by Sf9 insect cells , with GST labeled tag. ,

HY-P703079

	DNASE1L3 Protein, Human (His) Deoxyribonuclease gamma; Deoxyribonuclease I like 3; Deoxyribonuclease I like III; Deoxyribonuclease I-like 3; DHP 2; DHP2; DNAS1L3; DNase gamma; DNase I homolog protein 2; DNase I homolog protein DHP2; DNase I like 3; DNase I-like 3; DNASE1L3; DNSL3_HUMAN; Liver and spleen DNase; LS DNase; LS-DNase; LSD; SLEB 16; SLEB16	Human	E. coli
	DNASE1L3 proteolytically cleaves single- and double-stranded DNA and generates fragments with 3'-OH termini. It can cleave chromatin, nucleosomes, and liposome-coated DNA. DNASE1L3 Protein, Human (His) is the recombinant human-derived DNASE1L3 protein, expressed by E. coli , with C-10*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17447AS

(1S,2R)-Tranylcypromine-d5 hydrochloride

(1S,2R)-Tranylcypromine-d₅ (hydrochloride) is the deuterium labeled Tranylcypromine hydrochloride[1]. Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression[2][3][4].

HY-17447SA

Tranylcypromine-d5 hydrochloride

Tranylcypromine-d₅ (hydrochloride) is a deuterium labeled (rel)-Tranylcypromine hydrochloride. Tranylcypromine hydrochloride is an irreversible, nonselective monoamine oxidase (MAO) inhibitor used in the treatment of depression. Tranylcypromine hydrochloride is also a lysine-specific demethylase 1 (LSD1) inhibitor, suppresses lesion growth and improves generalized hyperalgesia in mouse with induced endometriosis[1][2].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80731

	KDM1A Antibody (YA718) KDM1A; AOF2; KDM1; KIAA0601; LSD1; Lysine-specific histone demethylase 1A; BRAF35-HDAC complex protein BHC110; Flavin-containing amine oxidase domain-containing protein 2	WB	Human, Mouse, Monkey
	KDM1A Antibody (YA718) is a non-conjugated and Mouse origined monoclonal antibody about 93 kDa, targeting to KDM1A (1B2). It can be used for WB assays with tag free, in the background of Human, Mouse, Monkey.

HY-P83638

	KDM1B Antibody (YA3383) AOF1; KDM1B; LSD2; Lysine-specific histone demethylase 1B; Lysine-specific histone demethylase 2	WB, ICC/IF, IP, FC	Human, Mouse, Rat
	KDM1B Antibody (YA3383) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3383), targeting KDM1B, with a predicted molecular weight of 92 kDa (observed band size: 92 kDa). KDM1B Antibody (YA3383) can be used for WB, ICC/IF, IP, FC experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-145259

HDAC6-IN-3		Alkynes
HDAC6-IN-3 (Compound 14), an antiprostate cancer agent, is a potent, orally active HDAC6 inhibitor with IC₅₀s ranging from 0.02-1.54 μM for HDAC1/2/3/6/8/10. HDAC6-IN-3 is also an effective MAO-A (IC₅₀=0.79 μM) and *LSD1* inhibitor . HDAC6-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.